Cargando…

Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model

PURPOSE: The aim of this study was to evaluate changes in body weight, liver weight, blood glucose, liver injury markers, pro-inflammatory factors and oxidative stress marker levels in obese mice with HFD induced NAFLD after semaglutide use. PATIENTS AND METHODS: The 24 C57BL6J mice were randomly di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niu, Shu, Chen, Shuchun, Chen, Xing, Ren, Qingjuan, Yue, Lin, Pan, Xiaoyu, Zhao, Huiying, Li, Zelin, Chen, Xiaoyi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780435/ https://www.ncbi.nlm.nih.gov/pubmed/36568109 http://dx.doi.org/10.3389/fendo.2022.1046130

Ejemplares similares

Effects of semaglutide on vascular structure and proteomics in high-fat diet-induced obese mice
por: Yue, Lin, et al.
Publicado: (2022)

An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism
por: Ren, Qingjuan, et al.
Publicado: (2022)

Metabolomics Provides Insights into Renoprotective Effects of Semaglutide in Obese Mice
por: Chen, Xing, et al.
Publicado: (2022)

Effect of semaglutide and empagliflozin on cognitive function and hippocampal phosphoproteomic in obese mice
por: Chen, Xiaoyi, et al.
Publicado: (2023)

Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice
por: Niu, Shu, et al.
Publicado: (2023)

Proteomic analysis reveals semaglutide impacts lipogenic protein expression in epididymal adipose tissue of obese mice
por: Zhu, Ruiyi, et al.
Publicado: (2023)

UTP14A, DKC1, DDX10, PinX1, and ESF1 Modulate Cardiac Angiogenesis Leading to Obesity-Induced Cardiac Injury
por: Pan, Xiaoyu, et al.
Publicado: (2022)

Effect of high-fat diet and empagliflozin on cardiac proteins in mice
por: Pan, Xiaoyu, et al.
Publicado: (2022)

Effects of Semaglutide on Cardiac Protein Expression and Cardiac Function of Obese Mice
por: Pan, Xiaoyu, et al.
Publicado: (2022)

Phosphorylated proteomics-based analysis of the effects of semaglutide on hippocampi of high-fat diet-induced-obese mice
por: Chen, Xiaoyi, et al.
Publicado: (2023)

Correlation of Body Mass Index with Clinicopathologic Parameters in Patients with Idiopathic Membranous Nephropathy
por: Chen, Xing, et al.
Publicado: (2022)

Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Corrigendum: Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Correlation between Cardiac Ultrasound Index and Cardiovascular Risk in Healthy Obese and Overweight Populations
por: Pan, Xiaoyu, et al.
Publicado: (2022)

Correlation of Obesity and Overweight with Cervical Vascular Function Among Healthy Populations
por: Pan, Xiaoyu, et al.
Publicado: (2022)

The Discovery and Development of Liraglutide and Semaglutide
por: Knudsen, Lotte Bjerre, et al.
Publicado: (2019)

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation
por: Meier, Juris J.
Publicado: (2021)

Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide
por: Gallwitz, Baptist, et al.
Publicado: (2021)

Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma
por: Jeong, Seogsong, et al.
Publicado: (2023)

A Novel Phenotype of Germline Pathogenic Variants in MAX: Concurrence of Pheochromocytoma and Ganglioneuroma in a Chinese Family and Literature Review
por: Chang, Xiaoyan, et al.
Publicado: (2020)

Resveratrol Reduces Glucolipid Metabolic Dysfunction and Learning and Memory Impairment in a NAFLD Rat Model: Involvement in Regulating the Imbalance of Nesfatin-1 Abundance and Copine 6 Expression
por: Chen, Xing-Xing, et al.
Publicado: (2019)

Selenoneine Ameliorates Hepatocellular Injury and Hepatic Steatosis in a Mouse Model of NAFLD
por: Miyata, Masaaki, et al.
Publicado: (2020)

Comparative Study of Different Diets-Induced NAFLD Models of Zebrafish
por: Chen, Bo, et al.
Publicado: (2018)

Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China
por: Wang, Yuying, et al.
Publicado: (2022)

Editorial: The NAFLD-MAFLD conundrum
por: Dalbeni, Andrea, et al.
Publicado: (2023)

The role of FOXA family transcription factors in glucolipid metabolism and NAFLD
por: Yu, Chuchu, et al.
Publicado: (2023)

Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
por: Rong, Li, et al.
Publicado: (2023)

Vitamin D improves hepatic steatosis in NAFLD via regulation of fatty acid uptake and β-oxidation
por: Du, Tingwan, et al.
Publicado: (2023)

Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain
por: Garcia de Lucas, Maria Dolores, et al.
Publicado: (2022)

Serum metabolomic profiling unveils distinct sex-related metabolic patterns in NAFLD
por: Fotakis, Charalambos, et al.
Publicado: (2023)

Verapamil Ameliorates Hepatic Metaflammation by Inhibiting Thioredoxin-Interacting Protein/NLRP3 Pathways
por: Zhou, Feng, et al.
Publicado: (2018)

Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
por: Nauck, Michael A., et al.
Publicado: (2021)

Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials
por: Zhang, Rui, et al.
Publicado: (2023)

Identification of ribosomal protein family as immune-cell-related biomarkers of NAFLD by bioinformatics and experimental analyses
por: Li, Gerui, et al.
Publicado: (2023)

MBOAT7 rs641738 (C>T) is associated with NAFLD progression in men and decreased ASCVD risk in elder Chinese population
por: Xu, Xiaoyi, et al.
Publicado: (2023)

Glucokinase regulatory protein: a balancing act between glucose and lipid metabolism in NAFLD
por: Zhang, Ziqi, et al.
Publicado: (2023)

Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations
por: Meier, Juris J., et al.
Publicado: (2021)

Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report
por: Martínez-Montoro, José Ignacio, et al.
Publicado: (2022)

Sensitivity to Thyroid Hormone Indices Are Closely Associated With NAFLD
por: Lai, Shuiqing, et al.
Publicado: (2021)

Editorial: Pharmacology and treatment methods for NAFLD in the context of diabetes
por: Abu-Farha, Mohamed, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nhjhq9ha5mb9a4n187mpb3knvg